Rosemary Berardi, Pharm.D.
Professor of Pharmacy
and Clinical Pharmacist (U-M Hospitals)

Pharm.D., University of Michigan

Phone: (313) 763-2350       Fax: (313) 763-2022
E-mail: berardi@umich.edu

 
Berardi Appointed to FDA Advisory Committee
Rosemary Berardi, PharmD'68, a professor at the College who holds a joint appointment as a clinical pharmacist at U-M Hospitals, began a four-year term on the U.S. Food and Drug Administration (FDA) Gastrointestinal Drugs Advisory (GDA) Committee in November 1996.
 
She is the only pharmacist who sits on the 11-member committee.
 
"The Gastrointestinal Drugs Advisory Committee doesn't approve drugs, per se, but one of its charges is to review clinical trial data and then recommend, or refuse to recommend, approval," Berardi explains.
 
In addition to the GDA Committee, there are FDA advisory committees for anesthesiology, respiratory therapy, clinical chemistry and toxicology, urology, hematology, pathology, immunology, microbiology, radiology, and other areas of medical specialty. Each committee is comprised of outside experts who are convened by federal agencies to make recommendations on agency actions and to aid in decision-making on drugs, biologics, and medical devices.
 
Berardi's selection followed several interviews spread over two years with national pharmacy associations, various consumers groups and finally, the FDA.
 
"There are many health care professionals who participate in the selection and management of drug therapies for patients," she reflects. "As a pharmacist, I view my presence on the committee primarily as that of an advocate for patient interests. That's always been my personal orientation. It's the orientation I teach to my students, and it's probably why the consumer groups who interviewed me specifically endorsed me."
 
Given her orientation, Berardi's intent is to balance the hard science of the drug approval process with a concern for the issues of compliance, cost effectiveness, safety, and efficacy.
 
Gastroenterology, Berardi's area of specialty, has been in the medical spotlight for the last few years following discoveries that Helicobacter pylori (H. pylori) bacteria causes the majority of peptic ulcer disease. Peptic ulcer disease affects as many as 20 percent of Americans at some time in their lives, and has been linked to another 20 million cases of chronic gastritis in the U.S. These discoveries have revolutionized the treatment of peptic ulcer disease since H. pylori infection can be successfully eradicated, without recurrence, in about 90 percent of all patients. In addition to being a leading cause of peptic ulcer disease, H. pylori has been labeled a Class One carcinogen and has been linked to gastric cancer.
 
Berardi frequently speaks on the topic of H. pylori infection to pharmacy and physician groups.
 
"Antibiotic therapy has become the treatment of choice, but until recently, there was no FDA approved regimen," she says. Such regimens are complicated by the fact that exposure to antibiotics contributes to the growing problem of antibiotic resistant organisms.
 
"This is an exciting time to be on the FDA's GDA Committee because there are so many things going on including the introduction of more H. pylori regimens," Berardi says.
 


[ Pharmacy Homepage | Table of Contents | Mail Pharmacy | U of M Homepage ]